Senhwa Biosciences Completes Patient Enrollment for Cancer Drug Trial
Senhwa Biosciences has completed enrollment for its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors. A clinical study report is expected in Q1 2027.
Senhwa Biosciences announced the completion of patient enrollment for its Phase 1b expansion trial. The study is evaluating pidnarulex (CX-5461) as a monotherapy in patients diagnosed with advanced solid tumors that possess BRCA1/2, PALB2, or other homologous recombination repair (HRR) pathway gene mutations.
The company focuses on developing oncology treatments, aiming to provide new therapeutic options for patients with rare cancers or those who have not responded to current treatments.
A clinical study report (CSR) is anticipated in the first quarter of 2027. This report will guide the future development path for pidnarulex in treating advanced solid tumors.